FDA: HIV medicine Kaletra shouldn't be given to newborns

03/8/2011 | Reuters

The FDA warned against giving Abbott Laboratories' Kaletra to HIV-positive infants because the drug might increase the risk of adverse events. "The use of Kaletra oral solution should be avoided in premature babies until 14 days after their due date, or in full-term babies younger than 14 days of age unless a health care professional believes that the benefit of using Kaletra oral solution to treat HIV infection immediately after birth outweighs the potential risks," the agency said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care